High METTL3 (Vu et al., 2017), WTAP (Bansal et al., 2014; Naren et al., 2021), FTO (Li et al., 2017c), ALKBH5 (Shen et al., 2020a; Wang et al., 2020b), and YTHDF2 (Paris et al., 2019) expression has been observed in all subtypes of acute myelogenous leukaemia (AML), and high WTAP (Naren et al., 2021), ALKBH5 (Shen et al., 2020a; Wang et al., 2020b) and IGF2BP1 expression (Elcheva et al., 2020) are related to the poor prognosis of AML patients. Here, IGF2BP1 is linked to acute myeloid leukemia.